Imeglimin is a Small Molecule owned by Poxel, and is involved in 38 clinical trials, of which 32 were completed, and 6 are ongoing.

Imeglimin acts as mitochondrial bioenergetic enhancer. It directly targets the three main organs involved in glucose regulation through inhibition of oxidative phosphorylation. It inhibits hepatic gluconeogenesis, increases muscle glucose uptake through restoring red and mixed muscle glucose consumption with an insulin-independent mechanism, and restores normal insulin secretion through a glucose-dependent mechanism. By targeting mitochondria, the drug candidate enhances both glucose-dependent insulin secretion and sensitivity.

The revenue for Imeglimin is expected to reach a total of $1.8bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Imeglimin NPV Report.

Imeglimin is currently owned by Poxel. Sumitomo Pharma is the other company associated in development or marketing of Imeglimin.

Imeglimin Overview

Imeglimin (Twymeeg) is an antidiabetic agent. It is formulated as film coated tablets for oral route of administration. Twymeeg is indicated for the treatment of type 2 diabetes.

Imeglimin (EMD-387008) is under development for the treatment of type II diabetes. The drug candidate is administered orally in the form of tablet. It is a new chemical entity. Imeglimin is a first in a tetrahydrotriazine-containing class of anti-diabetic drugs, the Glimins. It was also under development for diabetic cardiomyopathy and chronic kidney disease stage 3b/4.

Sumitomo Pharma Overview

Sumitomo Pharma, a subsidiary of Sumitomo Chemical Co Ltd develops, manufactures, sells, imports and exports pharmaceutical products. The company drugs are focused on major therapeutic areas which include regenerative diseases, oncology, psychiatry and neurology and infectious diseases. It also offers veterinary medicines for companion animals, primarily dogs, and cats, as well as for livestock such as cattle, swine, poultry, horses, and aquacultured fish. It also offers food additives, chemical product materials, food ingredients, and other products. Sumitomo Dainippon has research laboratories and manufacturing and distribution facilities in Japan. The company operates through subsidiaries and offices in North America, Europe, and Asia Pacific. Sumitomo Pharma is headquartered in Osaka, Japan.

The company reported revenues of (Yen) JPY560,035 million for the fiscal year ended March 2022 (FY2022), an increase of 8.5% over FY2021. In FY2022, the company’s operating margin was 10.8%, compared to an operating margin of 13.8% in FY2021. In FY2022, the company recorded a net margin of 10.1%, compared to a net margin of 10.9% in FY2021. The company reported revenues of JPY159,413 million for the second quarter ended September 2022, a decrease of 0.3% over the previous quarter.

Quick View – Imeglimin

Report Segments
  • Innovator (NME)
Drug Name
  • Imeglimin
Administration Pathway
  • Oral
Therapeutic Areas
  • Genito Urinary System And Sex Hormones
  • Metabolic Disorders
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.